<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gourlay, Annabelle</style></author><author><style face="normal" font="default" size="100%">Noori, Teymur</style></author><author><style face="normal" font="default" size="100%">Pharris, Anastasia</style></author><author><style face="normal" font="default" size="100%">Axelsson, Maria</style></author><author><style face="normal" font="default" size="100%">Costagliola, Dominique</style></author><author><style face="normal" font="default" size="100%">Cowan, Susan</style></author><author><style face="normal" font="default" size="100%">Croxford, Sara</style></author><author><style face="normal" font="default" size="100%">d'Arminio Monforte, Antonella</style></author><author><style face="normal" font="default" size="100%">Del Amo, Julia</style></author><author><style face="normal" font="default" size="100%">Delpech, Valerie</style></author><author><style face="normal" font="default" size="100%">Díaz, Asunción</style></author><author><style face="normal" font="default" size="100%">Girardi, Enrico</style></author><author><style face="normal" font="default" size="100%">Gunsenheimer-Bartmeyer, Barbara</style></author><author><style face="normal" font="default" size="100%">Hernando, Victoria</style></author><author><style face="normal" font="default" size="100%">Jose, Sophie</style></author><author><style face="normal" font="default" size="100%">Leierer, Gisela</style></author><author><style face="normal" font="default" size="100%">Nikolopoulos, Georgios</style></author><author><style face="normal" font="default" size="100%">Obel, Niels</style></author><author><style face="normal" font="default" size="100%">Op de Coul, Eline</style></author><author><style face="normal" font="default" size="100%">Paraskeva, Dimitra</style></author><author><style face="normal" font="default" size="100%">Reiss, Peter</style></author><author><style face="normal" font="default" size="100%">Sabin, Caroline</style></author><author><style face="normal" font="default" size="100%">André Sasse</style></author><author><style face="normal" font="default" size="100%">Schmid, Daniela</style></author><author><style face="normal" font="default" size="100%">Sonnerborg, Anders</style></author><author><style face="normal" font="default" size="100%">Spina, Alexander</style></author><author><style face="normal" font="default" size="100%">Suligoi, Barbara</style></author><author><style face="normal" font="default" size="100%">Supervie, Virginie</style></author><author><style face="normal" font="default" size="100%">Touloumi, Giota</style></author><author><style face="normal" font="default" size="100%">Dominique Van Beckhoven</style></author><author><style face="normal" font="default" size="100%">van Sighem, Ard</style></author><author><style face="normal" font="default" size="100%">Vourli, Georgia</style></author><author><style face="normal" font="default" size="100%">Zangerle, Robert</style></author><author><style face="normal" font="default" size="100%">Porter, Kholoud</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">European HIV Continuum of Care Working Group</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">The Human Immunodeficiency Virus Continuum of Care in European Union Countries in 2013: Data and Challenges.</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Anti-HIV Agents</style></keyword><keyword><style  face="normal" font="default" size="100%">Antiretroviral Therapy, Highly Active</style></keyword><keyword><style  face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Continuity of Patient Care</style></keyword><keyword><style  face="normal" font="default" size="100%">Disease Eradication</style></keyword><keyword><style  face="normal" font="default" size="100%">European Union</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">HIV</style></keyword><keyword><style  face="normal" font="default" size="100%">HIV Infections</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Mass Screening</style></keyword><keyword><style  face="normal" font="default" size="100%">prevalence</style></keyword><keyword><style  face="normal" font="default" size="100%">United Nations</style></keyword><keyword><style  face="normal" font="default" size="100%">World Health Organization</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2017 Jun 15</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">64</style></volume><pages><style face="normal" font="default" size="100%">1644-1656</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND.: &lt;/b&gt;The Joint United Nations Programme on HIV/AIDS (UNAIDS) has set a &quot;90-90-90&quot; target to curb the human immunodeficiency virus (HIV) epidemic by 2020, but methods used to assess whether countries have reached this target are not standardized, hindering comparisons.&lt;/p&gt;&lt;p&gt;&lt;b&gt;METHODS.: &lt;/b&gt;Through a collaboration formed by the European Centre for Disease Prevention and Control (ECDC) with European HIV cohorts and surveillance agencies, we constructed a standardized, 4-stage continuum of HIV care for 11 European Union countries for 2013. Stages were defined as (1) number of people living with HIV in the country by end of 2013; (2) proportion of stage 1 ever diagnosed; (3) proportion of stage 2 that ever initiated ART; and (4) proportion of stage 3 who became virally suppressed (≤200 copies/mL). Case surveillance data were used primarily to derive stages 1 (using back-calculation models) and 2, and cohort data for stages 3 and 4.&lt;/p&gt;&lt;p&gt;&lt;b&gt;RESULTS.: &lt;/b&gt;In 2013, 674500 people in the 11 countries were estimated to be living with HIV, ranging from 5500 to 153400 in each country. Overall HIV prevalence was 0.22% (range, 0.09%-0.36%). Overall proportions of each previous stage were 84% diagnosed, 84% on ART, and 85% virally suppressed (60% of people living with HIV). Two countries achieved ≥90% for all stages, and more than half had reached ≥90% for at least 1 stage.&lt;/p&gt;&lt;p&gt;&lt;b&gt;CONCLUSIONS.: &lt;/b&gt;European Union countries are nearing the 90-90-90 target. Reducing the proportion undiagnosed remains the greatest barrier to achieving this target, suggesting that further efforts are needed to improve HIV testing rates. Standardizing methods to derive comparable continuums of care remains a challenge.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">12</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/28369283?dopt=Abstract</style></custom1></record></records></xml>